CHMP Jul 25, 2022 EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca Jul 25, 2022 Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL Jul 22, 2022 Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma Jun 27, 2022 EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications Jun 24, 2022 EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients Jun 22, 2022 European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC May 4, 2022 Novartis Nabs European Approval for Kymriah in Follicular Lymphoma Apr 22, 2022 EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation Mar 28, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers Mar 25, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors Mar 25, 2022 EMA's CHMP Issues Positive Recommendations for Novartis' Kymriah, Janssen's Carvykti Feb 25, 2022 CHMP Recommends Approval for Opdivo in PD-L1-Positive Esophageal, Urothelial Cancers Feb 25, 2022 CHMP Issues Positive Opinion for Immunocore's Kimmtrak as Metastatic Uveal Melanoma Treatment Jan 28, 2022 EMA's CHMP Issues Positive Opinion on BMS' Breyanzi for Lymphoma Patients Dec 28, 2021 EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer Dec 17, 2021 EMA's CHMP Issues Positive Opinion on Merck KGaA's Tepmetko for Lung Cancer Subgroup Nov 30, 2021 EMA Accepts Marketing Application for Atara Biotherapeutics' Tabelecleucel Nov 12, 2021 CHMP Recommends Amgen's Lumykras for KRAS G12C-Mutated NSCLC Oct 15, 2021 CHMP Recommends Gilead's Trodelvy for Pretreated TNBC Sep 17, 2021 CHMP Recommends BMS' Opdivo Plus Chemo for First-Line PD-L1-Positive Gastric Cancers Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer